Nascimento IS, et al. - This research intended to prospectively evaluate the role of anti-ß2-glycoprotein I domain I antibody (aß2GPI-DI) and the Global Antiphospholipid Syndrome Score (GAPSS) in distinguishing antiphospholipid syndrome (APS) individuals at higher risk of a new event. Between May 2013 and July 2017, thrombotic APS individuals were followed. Researchers assessed lupus anticoagulant, IgG/IgM anticardiolipin, anti-ß2-glycoprotein I, antiphosphatidylserine-prothrombin (aPS/PT) and IgG aß2GPI-DI, and calculated GAPSS for each individual at baseline. A significant association was found between a validated risk score such as GAPSS and the novel antiphospholipid antibody aß2GPI-DI. Further research is required. Nevertheless, in APS, one could speculate a role of aß2GPI-DI as a risk-stratifying tool for thrombotic events.